SpaceX vs. Rocket Lab: Which Space Stock Has More Room to Run?

SpaceX is expected to debut at a $2 trillion market cap versus Rocket Lab’s $85.7 billion, while 2025 revenue is projected at $18.7 billion for SpaceX and $602 million for Rocket Lab. On valuation, SpaceX trades at about 107x 2025 sales versus Rocket Lab at 142x, making SpaceX look cheaper despite its much larger size. The article argues that SpaceX’s far greater R&D capacity, including $9.5 billion spent in 2025, may give it the stronger long-term growth case.

Analysis

The market is misframing this as a simple “bigger upside” contest. The more important distinction is capital intensity: the winner in space is likely to be the company that can convert scale into a self-funding R&D flywheel, and that structurally favors the business with deeper gross profit and a much larger balance sheet. That creates a second-order implication for public comps: a richly valued private leader can actually compress the valuation ceiling for smaller listed names if it keeps reinvesting at a higher absolute dollar pace and widens the technological gap.

For Rocket Lab, the risk is not just that it remains unprofitable; it is that its incremental capital requirement stays high relative to its revenue base, keeping it trapped in a “good growth, bad dilution” loop. If the next major product cycle slips by even 2-3 quarters, the market may stop valuing it on revenue growth and start penalizing it on cash burn durability. SpaceX, by contrast, can sustain long-duration R&D and still retain strategic optionality, which is exactly the kind of advantage that usually shows up only after public investors have already paid up for the smaller rival.

The contrarian read is that the apparent bargain may not be the cheaper multiple, but the one with more credible path to technological moat expansion. If SpaceX’s disclosures validate sustained high gross margins, then the “law of large numbers” narrative is broken, and the market may begin to underwrite a much longer runway for its adjacent ecosystem than for Rocket Lab’s single-product progression. That would be bullish for select suppliers and enabling technologies, but bearish for any assumption that smaller listed space names automatically get re-rated upward on scarcity alone.

Near term, this is less a days trade than a months-to-years positioning issue. The catalyst is the IPO and first few quarters of public disclosure: if the margin structure and R&D cadence hold, the relative multiple gap can re-rate quickly; if execution stumbles, the entire sector likely de-risks. The key tail risk is financing fatigue in the smaller name if investors decide the path to profitability keeps extending.

Key Decisions for Investors

• Avoid chasing Rocket Lab into the IPO window; the stock is vulnerable to a post-event multiple reset if investors refocus on cash burn rather than revenue growth. Time horizon: 1-3 months.
• Relative value: favor long SpaceX exposure on the IPO if accessible, funded by a short Rocket Lab basket or put spread, on the thesis that scale + gross margin + R&D intensity deserve the premium. Risk/reward improves if the public market initially over-anchors to headline market cap.
• For public-market substitutes, build a small long in NVDA and INTC only as indirect beneficiaries of space-related compute/semiconductor demand, but treat it as a low-conviction thematic hedge rather than core alpha. Time horizon: 6-12 months.
• Use NDAQ as a watchlist name for IPO activity rather than a direct trade; a high-profile listing can boost issuance sentiment, but the effect is usually short-lived and not enough to justify a standalone position absent broader IPO breadth. Time horizon: days to weeks.
• If forced into a pair, prefer long the better-capitalized growth platform versus short the smaller high-burn operator; the trade should be sized for volatility because the catalyst is narrative-driven and could gap on any contract or launch headline.